Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer

被引:359
作者
Robnett, TJ [1 ]
Machtay, M [1 ]
Vines, EF [1 ]
McKenna, MG [1 ]
Algazy, KM [1 ]
McKenna, WG [1 ]
机构
[1] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 48卷 / 01期
关键词
lung cancer; radiation pneumonitis; chemoradiation;
D O I
10.1016/S0360-3016(00)00648-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To identify factors that may predict for severe radiation pneumonitis or pneumonopathy (RP), we reviewed a set of simple, commonly available characteristics. Methods and Materials: Medical records of 148 lung cancer patients with good performance status (ECOG 0-1) treated definitively with chemoradiation from 6/92-6/98 at the University of Pennsylvania were reviewed. Actuarial survival and the crude rate of severe radiation pneumonitis were determined as a function of several variables. Potential predictive factors examined included age, gender, histology, stage, pulmonary function, performance status (0 vs. 1), weight loss, tumor location, radiation dose, initial radiation held size, chemotherapy regimen, and timing of chemotherapy. Univariate analysis (log-rank test) was performed for each variable. Multivariate analysis was performed using linear regression. Results: Median survival for the entire cohort was 14.7 months. Four patients were inevaluable for pneumonitis due to early death from progressive disease. Of the remaining 144 evaluable patients, 12 (8.3%) experienced severe RP. The most significant factor predicting for severe RP was performance status (p < 0.003). The risk of severe RP was 16% for PS-1 patients vs. 2% for PS-0 patients. Women were significantly more likely to develop severe RP than men (p = 0.01). Among 67 patients for whom pre-radiation therapy pulmonary function data were available, forced expiratory volume of the lung in 1 second (FEV1) was also significant (p = 0.03). No patient suffering severe RP had a pretreatment FEV1 > 2.0 liters. The median radiation dose was 59.2 Gy and median initial radiation held size was 228 cm(2). Neither radiotherapy factor predicted for RP. Other factors studied, including chemotherapy drugs, and schedule, also were not significant predictors of severe RP. Conclusions: Pretreatment performance status, gender, and FEV1 are significant predictors of severe radiation pneumonopathy, at least when using conventional radiation fields and doses. Complex radiation dose-volume algorithms that attempt to predict lung complication probabilities should probably incorporate these simply obtained clinical parameters. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 27 条
[1]
*AJCC, 1997, AM JOINT COMM CANC C
[2]
[Anonymous], APPL REGRESSION ANAL
[3]
STRATEGY FOR DOSE-ESCALATION USING 3-DIMENSIONAL CONFORMAL RADIATION-THERAPY FOR LUNG-CANCER [J].
ARMSTRONG, JG ;
ZELEFSKY, MJ ;
LEIBEL, SA ;
BURNAM, C ;
HAN, C ;
HARRISON, LB ;
KUTCHER, GJ ;
FUKS, ZY .
ANNALS OF ONCOLOGY, 1995, 6 (07) :693-697
[4]
BONOMI P, 1996, SEMIN ONCOL S16, V6, P102
[5]
THE INFLUENCE OF FIELD SIZE AND OTHER TREATMENT FACTORS ON PULMONARY TOXICITY FOLLOWING HYPERFRACTIONATED IRRADIATION FOR INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC) - ANALYSIS OF A RADIATION-THERAPY ONCOLOGY GROUP (RTOG) PROTOCOL [J].
BYHARDT, RW ;
MARTIN, L ;
PAJAK, TF ;
SHIN, KH ;
EMAMI, B ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03) :537-544
[6]
Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung [J].
Byhardt, RW ;
Scott, C ;
Sause, WT ;
Emami, B ;
Komaki, R ;
Fisher, B ;
Lee, JS ;
Lawton, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (03) :469-478
[7]
THE EVOLUTION OF RADIATION-THERAPY ONCOLOGY GROUP (RTOG) PROTOCOLS FOR NONSMALL CELL LUNG-CANCER [J].
BYHARDT, RW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (05) :1513-1525
[8]
CHOI N C, 1985, Cancer Treatment Symposia, V2, P119
[9]
A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
DILLMAN, RO ;
SEAGREN, SL ;
PROPERT, KJ ;
GUERRA, J ;
EATON, WL ;
PERRY, MC ;
CAREY, RW ;
FREI, EF ;
GREEN, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945
[10]
Furuse K, 1997, ONCOLOGY, V54, P298